Observational Study Evaluating the Effect of a Biotherapy Treatment (Anti- RANKL Ligand Antibody: Denosumab) on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease Patients (HDENOBS)

NCT05234047 UNKNOWN

Aim of this study is to evaluate in a population of osteoporotic chronic kidney disease patients the effect of denosumab: * on coronary artery calcification scores evolution after 24 months of followup * on abdominal aorta calcification scores evolution after 24 months of followup * on bone mineral density (femoral T-score) at 24 months * on bone mineral density evolution (femoral T-score) after 24 months of follow-up * on bone mineral density evolution (lumbar T-score) after 24 months of follow-up * on parameters of bone remodelling after 24 months of follow-up * on cardiovascular morbidity (cardiovascular events) and mortality after 24 months of follow-up * the tolerance after 24 months of follow-up

Details

Lead sponsor	University Hospital, Montpellier
Status	UNKNOWN
Enrolment	21
Start date	2022-05
Completion	2025-02

Conditions

• Osteoporosis
• Chronic Kidney Disease 5D

Interventions

• MDCT (multidetector computed tomography)
• Dual-energy X-ray absorptiometry

Primary outcomes

• Relative variation of coronary calcification scores after 24 months of follow-up — 24 months after inclusion